Paolo Ghia
保罗·吉亚
MD, PhD
Professor of Medical Oncology; Director, Strategic Research Program on CLL, IRCCS Ospedale San Raffaele肿瘤内科学教授兼CLL战略研究项目主任
👥Biography 个人简介
Prof. Paolo Ghia is Italy's leading CLL expert and a pivotal European investigator who co-led the GLOW trial combining ibrutinib and venetoclax. His research spans CLL biology, prognostics, and therapeutic development including fixed-duration BTK-BCL2 combination regimens.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
GLOW Trial and BTK-BCL2 Combination
Co-led the GLOW trial demonstrating ibrutinib plus venetoclax fixed-duration doublet achieves deep MRD-negative remissions in frontline CLL, offering a chemotherapy-free time-limited alternative with durable PFS benefit.
CLL Molecular Prognostics
Made foundational contributions to understanding IGHV mutational status, ZAP-70, and CD38 as CLL prognostic markers, and helped establish ERIC guidelines for standardized MRD assessment in clinical trials.
Representative Works 代表性著作
Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (GLOW)
New England Journal of Medicine (2022)
Phase 3 GLOW trial showing ibrutinib-venetoclax superiority over chlorambucil-obinutuzumab in frontline CLL with high uMRD rates.
Zanubrutinib versus Bendamustine and Rituximab in Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Journal of Clinical Oncology (2021)
Established zanubrutinib as an effective frontline CLL option with a favorable safety profile compared to chemoimmunotherapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 保罗·吉亚 的研究动态
Follow Paolo Ghia's research updates
留下邮箱，当我们发布与 Paolo Ghia（Vita-Salute San Raffaele University, Milan）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment